Remibrutinib for peanut, milk, or egg allergies
Treatments studied
Part of Immune system & allergy clinical trials.
This study tests an investigational drug called remibrutinib to see if it can reduce allergic reactions to peanuts, milk, or eggs. It is for people aged 12 to 65 who have been diagnosed with a food allergy and are willing to participate in food challenges.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 65 years old.
- You must have a confirmed allergy to peanuts, milk, or eggs, shown by a blood test and a skin prick test.
- You must have a positive food challenge at the start of the study, meaning you react to a small amount of the allergen.
- You must be willing to avoid the allergen (peanut, milk, or egg) and any other foods you are allergic to during the study.
- You must not have used remibrutinib or other BTK inhibitors before.
- You must be able to attend study visits and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding tezepelumab (a biologic drug) to peanut oral immunotherapy can help people with peanut allergy better tolerate small amounts of peanut protein without having an allergic reaction.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
This study tests a new medicine called remibrutinib to see if it can reduce severe itching that has no clear cause. It aims to help people whose daily itching is very intense and not relieved by standard creams.
This trial tests a new medication called RPT904 in people with IgE-mediated food allergies to foods like peanut, milk, egg, cashew, or walnut. The goal is to see if it reduces allergic reactions when you eat a small amount of the food.
This program offers remibrutinib, an experimental oral medication, to adults with chronic spontaneous urticaria (long-lasting hives without a known trigger) that hasn't improved with standard antihistamines or omalizumab. It aims to see if this drug can reduce symptoms when other options haven't worked.
This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.
Hear when a new Peanut Allergy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.